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The nonclassical major histocompatibility complex of class II molecules
(ncMHCII) HLA-DM (DM) and HLA-DO (DO) feature essential functions for
the selection of the peptides that are displayed by classical MHCII proteins
(MHCII) for CD4+ Th cell surveillance. Thus, although the binding groove of
classical MHCII dictates the main features of the peptides displayed, ncMHCII
function defines the preferential loading of peptides from specific cellular com-
partments and the extent to which they are presented. DM acts as a chaperone
for classical MHCII molecules facilitating peptide exchange and thereby favoring
the binding of peptide-MHCII complexes of high kinetic stability mostly in late
endosomal compartments. DO on the other hand binds to DM blocking its
peptide-editing function in B cells and thymic epithelial cells, limiting DM activ-
ity in these cellular subsets. DM and DO distinct expression patterns therefore
define specific antigen presentation profiles that select unique peptide pools for
each set of antigen presenting cell. We have come a long way understanding the
mechanistic underpinnings of such distinct editing profiles and start to grasp the
implications for ncMHCII biological function. DM acts as filter for the selection
of immunodominant, pathogen-derived epitopes while DO blocks DM activity
under certain physiological conditions to promote tolerance to self. Interestingly,
recent findings have shown that the unexplored and neglected ncMHCII genetic
diversity modulates retroviral infection in mouse, and affects human ncMHCII
function. This review aims at highlighting the importance of ncMHCII function
for CD4+ Th cell responses while integrating and evaluating what could be the
impact of distinct editing profiles because of natural genetic variations.
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1 | INTRODUCTION
Classical human leukocyte antigens of class II (HLAII)
also called major histocompatibility complex (MHCII)
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proteins display antigenic peptides, primarily from extra-
cellular proteins, at the cell surface of professional antigen
presenting cells (pAPCs). The pool of peptides presented
by MHCII proteins (the “immunopeptidome”) is surveyed
by CD4+ Th cells. Noteworthy, although a typical pAPC
displays around 105 surface-peptide-MHCII molecules in
steady state, a very low number of pMHCII complexes
(10-200) loaded with immunogenic peptides are capable of
providing the trigger for activation of cognate T cells.1,2
Therefore, even subtle changes in the immunopeptidome
composition can have the potential to affect CD4+ Th
responses. In this context, the immune system has evolved
and optimized a complex and regulated peptide exchange
mechanism that ensure the optimal display of peptide
antigens under steady-state conditions and upon immuno-
logical challenges on different types of pAPCs. These
mechanisms of peptide-repertoire selection rely on the dif-
ferential expression of two nonclassical MHCII proteins
(ncMHCII): HLA-DM (DM) and HLA-DO (DO). DM and
DO map to the same genetic locus as classical MHCIIs but
they are of very limited polymorphism and presumably do
not bind peptides themselves. DM acts as a chaperone
with a MHCII-peptide exchange catalyst function
expressed in all pAPCs. DM function selects peptides with
high kinetic stability thereby promoting the cell surface
display of long-lived peptide-MHCII complexes (pMHCII),
usually named immunodominant CD4+ Th cell epitopes
when they raise immune responses. This function contrib-
utes to selection of pathogen-derived peptides upon infec-
tion promoting T cell immunity toward the pathogen. DO
on the other hand is a MHCII-substrate mimic that binds
tightly to DM and inhibits its function, primarily in B cells
and thymic epithelial cells. DO function is restricted to
specific developmental conditions of B cells,3 and to the
thymic environment where T cells undergo negative and
positive selection.4 In both cases, DO has been proposed to
broaden the immunopeptidome facilitating the develop-
ment of tolerance to self-antigens. Thus, while the biologi-
cal function of antigen presentation is mainly carried out
by MHCII, ncMHCII have evolved to influence peptide
selection. Ultimately, ncMHCII function governs whether
and which antigen specific T cells will become activated.
2 | CLASSICAL AND
NONCLASSICAL HLAII GENES
MHCII molecules, classical and nonclassical, are
heterodimers, and the combination of the polypeptide
variants encoded by alpha (A) and beta (B) genes yields
the functional molecules called allotypes. The A and B
genes encoding for MHCII proteins are arranged as pairs,
with HLA-DR and HLA-DO being the exception to this
rule. There is only one HLA-DRA gene and for each indi-
vidual there are potentially several HLA-DRB genes.
Thus, DRA dimerizes with any of the polypeptides
encoded by functional HLA-DRB genes for an individual.
HLA-DOA and DOB genes are spaced by several genes
related to MHC class I antigen presentation (see general
architecture of the HLAII locus in Figure 1A). HLA genes
arose from a common ancestor through gene duplication
events.5 Hughes and collaborators analyzed the sequence
of MHCII genes and proposed that while HLAII genes
are subject of balancing selection, nonclassical genes
undergo purifying or directional selection.6 The most
important evolutionary pressure acting on HLA genes is
the interaction of the host with pathogens.7 Thus, the
highly polymorphic nature of classical MHCII is an
advantage to overcome infections, while one could
assume that ncMHCII genes have been optimally evolved
to perform their functions. For ncMHCII, despite the
rather low polymorphic degree recent findings from our
lab,8,9 and from Denzin-Golovkina10 have shown that
ncMHCII genetic variants are functionally distinct.
Whether or not specific ncHLAII genetic variants have
been selected for based on their functional profiles, and
whether these variants indeed contribute to or provide
any evolutionary advantage that has been fixed over time
remains to be determined.
The MHC features a very strong linkage disequilib-
rium (LD), hence HLA genes associate in blocks that do
not segregate upon recombination. These blocks are con-
sidered as haplotypes which have been studied mostly for
their association to diseases, mainly autoimmunity.11
Haplotypes described to date include DR and DQ genes,
while haplotype segregation of DP genes has only been
recently scored in a systematic manner in the context of
unrelated hematologic stem cell transplantation
(HSCT).12 DP genes have been traditionally neglected
from haplotype analysis because of the presence of a
recombination hotspot in the HLA class II locus that
leads to a decreased LD between the genes on each side
of DMB and DQB.13 However, DP mismatches have been
related to survival rates and clinical conditions after
unrelated HSCT.14,15 Similarly, the potential contribution
of ncMHCII variants to haplotypes have been tradition-
ally ignored. In this case, the very low variation profiles
and our ignorance on their distinct functional profiles
would be the main argument for their exclusion from
haplotype analysis. Recent findings nevertheless have
shown the impact of distinct functional profiles of
ncMHCII on T cell activation9 and even responses to ret-
roviral infections.10 Thus, the inclusion of both, DP and
ncMHCII genes in haplotype analysis, already proposed
in the late 1990s,16 could provide additional insights into
relevant physiological and clinical processes. Noteworthy,
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with the exception of DOA all ncMHCII and DP genes
are considered to be part of the same block in the HLA
region. Of particular interest for this review, the modula-
tory effect on MHCII presentation imposed by allelic var-
iants of ncMHCII could affect epitope selection and
subsequent physiological processes (Figure 1B).
Classical and the ncHLAII HLA-DM genes are
expressed constitutively in pAPCs, but could also be
induced in response to cytokines in epithelial cells or
even T cells. In all cases, the expression of these genes is
dependent on the Class II Trans Activator (CIITA), the
master regulator for MHCII expression. Ubiquitously
expressed transcription factors bind to conserved ele-
ments on the MHCII promoters (W, X, X2, Y boxes) and
the CIITA acts as a platform bridging all these elements
to facilitate HLA transcription. Different promoters of the
CIITA are responsible for constitutive and induced HLA
expression and have been reviewed by Reith and col-
leagues.17 Interestingly, neither IFNγ nor IL10, but IL4
are able to induce DOA or DOB expression.18
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FIGURE 1 Overview of ncMHCII genetics and functions. A, The number of HLAII gene and protein variants with a frequency higher
than 1% is shown below a nonscaled representation of the MHCII locus (IPD-IMGT/HLA database).118 Colored boxes correspond to HLA
genes. The total number of variants reported by the ExAC consortia (ExAC)119 as well as the number of missense variants with frequencies
higher than 1% are also indicated. B, Schematic representation of the HLAII locus, including classical HLAII and ncHLAII. The strong linkage
disequilibrium in the HLA region defines ancestral HLA haplotypes. These haplotypes consist of a specific combination of HLAII genes
(indicated below the corresponding boxes). C, Overview of the cellular processes, and main route resulting in antigen presentation by MHCII in
pAPCs and B cells. DM activity in pAPCs results in the presentation of high affinity antigenic peptides, while its inhibition by DO in B-cells
impairs peptide exchange, thus in most MHCII allotypes this results in the presentation of CLIP. D, Model network of MHCII antigen
presentation adapted from Miller et al31 to indicate the impact of DM and DO function. Antigens derived from pathogens undergo different
processing routes. Each represented by the connections that lead to the final display in the lower row. For a specific pathogen-derived
immunodominant epitope (Imm epitope, red) the presence of DM (left) may allow loading onto MHCII by different distinct pathways. For
instance, in the presence of DO (right), the Imm. (immunodominant) Epitope may only be presented through one of the candidate routes. Note
that the depicted model will represent the impact of DM and DM+DO for single peptides or epitopes and thus, it does not represent the
predicted impact for the immunopeptidome. CLIP, class II invariant chain associated peptide; HLAII, human leukocyte antigens of class II;
MHCII, major histocompatibility complex of class II molecules; nc, nonclassical; pAPCs, professional antigen presenting cells
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Furthermore, CIITA itself is not sufficient to induce DOB
expression although it is required for its maximal expres-
sion. Thus, while DM follows the same expression pat-
tern as that from MHCII, DO seems to undergo a specific
program, not yet fully understood.
3 | GENERAL MECHANISMS OF
ANTIGEN PRESENTATION BY
MHCII MOLECULES
The cellular processes that result in the display of anti-
genic peptides on the cell surface of APCs for T cell sur-
veillance are collectively known as antigen presentation.19
At a minimum these mechanisms include: the regulated
gene expression of MHCII molecules; the control of their
recycling rate between the surface and intracellular com-
partments; antigen internalization and/or proteolytic deg-
radation; and finally, the active selection of peptides for
presentation by ncMHCII.
To date, there is the canonical pathway, as well as sev-
eral nonconventional pathways described for antigen pre-
sentation, which in sum, account for the display of
specific peptide repertoires. In the canonical pathway,
described for pAPCs not expressing DO, classical MHCII
proteins are synthesized in the ER and their binding
groove is chaperoned by a specific fragment of the CD74/
invariant chain (Ii) termed class II invariant chain associ-
ated peptide (CLIP). Ii not only chaperones the MHCII's
binding groove but also contributes to their sorting to the
Golgi apparatus and subsequently to the cell surface for
their reinternalization to late endosomal compartments.
Once in late endosomal compartments, MHCII proteins
encounter antigens mostly internalized by bulk liquid
phase endocytosis. The function of proteolytic activities
degrades most of the invariant chain, and the available
antigens. In these compartments the peptide-exchange
activity of DM contributes to release CLIP, and facilitates
the loading of higher affinity antigenic peptides.20 This
canonical pathway includes receptor-mediated endocytosis
by the B Cell Receptor, Fc receptors, or even MHCII. DM
therefore assumes a central role in antigen presentation as
it affects peptide exchange by all classical MHCII mole-
cules (DP, DQ, and DR) in every pAPC (Figure 1C). DO
function, however, has only been observed to date in par-
ticular cellular subsets including B and thymic epithelial
cells,4 leading as a direct consequence to the increased
presentation of CLIP peptides on these cells. (Figure 1C).
However, besides this rough distinction there are consider-
able differences between the expression patterns of
ncMHCII between subsets of prototypic APCs21,22 whose
potentially different contribution to CD4+ Th cell immune
responses has not yet been fully investigated.
Alternative pathways of antigen presentation have
been shown to be extremely important for infections23 or
even autoimmunity.24-26 Peptides or unfolded proteins
can bind to MHCII at the cell surface where they are
directly displayed for T cell recognition.27 Similarly
autophagocytosis can deliver cytosolic proteins to
endosomal compartments for MHCII antigen presenta-
tion.28 Exosome transfer of MHCII molecules, and their
cargoes further diversifies the potential conditions for
antigen presentation.29 Recent findings even show a
direct loading of MHCII molecules in the ER and Golgi
supported by alternative chaperones as described
below.30 Overall, a very attractive, and perhaps more
realistic picture of MHCII antigen presentation will
include interconnections between all these different
routes and processes as proposed by the Eisenlohr lab for
viral infections31,32 (Figure 1D).
4 | CLASSICAL MHCII PROTEINS,
THE NEED FOR AND THE
CONSEQUENCES OF PEPTIDE
EDITING
Classical HLAII proteins are not the primary focus of this
review, although to comprehend DM and DO function it is
essential to describe fundamental aspects of their biochemis-
try and cell biology. Their biological function is the display
of peptides available for binding, thereby providing CD4+ Th
cells with a global picture of the immune condition of the
individual. HLA-DP, −DQ, and -DR are heterodimers, with
a membrane distal domain built up by the two subunits that
define the peptide-binding groove.33 Noteworthy most of the
polymorphisms found in the genes encoding these proteins
lie at, or close to the structural elements defining the bind-
ing groove; therefore defining the nature of the peptides
presented to T cells, but also the interaction with DM.34
MHCII molecules bind peptides of 13 to 25 amino acids in
length.33 Peptide residues stick through their lateral chains
into MHCII cavities defined on the binding groove. The
most N-terminal residue of the peptide buried into one of
these cavities defines the so-called P1 pocket, and subse-
quent pockets toward the C-terminal region of the peptide
are named consecutively up to P9. Thus, the preference in
binding specific residues in each pocket define the so-called
binding motifs for each allotype conventionally used to pre-
dict peptide binding to MHCII molecules in silico.
A common aspect to all MHCII, is that they are ini-
tially chaperoned in the ER by the Ii. While the C-
terminal region of Ii is involved in cellular trafficking,
the CLIP region chaperones the binding groove of MHCII
preventing the premature binding of peptides in the ER
(reviewed in Reference 35). The relative affinity between
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MHCII and CLIP varies considerably between MHCII
allotypes, reaching up to 4-log-fold differences in IC50
values36 (Figure 2A). This feature makes a clear distinc-
tion between classical MHCIIs and their behavior as anti-
gen presenting molecules. Thus, MHCII allotypes with a
high affinity for CLIP require either high antigenic pep-
tide concentrations or HLA-DM function to exchange
CLIP, whereas low affinity binders do not require DM
function to exchange this peptide. An intriguing excep-
tion to the abovementioned MHCII-peptide binding rules
and the MHCII interaction with CLIP arise from the
results of our own lab. Structural and biochemical inves-
tigations demonstrated the class II invariant chain associ-
ated peptide (CLIP) could bind in two different
orientations to the common HLA-DR1 (DRA*01:01-
DRB1*01:01) MHCII molecule.37 To date, the biological
relevance of these findings has not been investigated.
Other relevant exceptions to the well-defined binding of
peptides to MHCII molecules that should be taken into
account are register shifting26 and the differential binding
of post-translationally modified peptides.38
The discovery of DM function and its importance
for peptide-repertoire selection is described below. How-
ever, it is worth mentioning here that, similar to the
allotype-specific requirements for the CLIP chaperoning of
the binding groove, MHCII molecules are also consider-
ably different in their ability to interact with DM and
therefore exchange peptides in a DM-catalyzed manner
(Figure 2B). The increase of peptide dissociation rates
dependent on the presence and the absence of DM was
described by Jensen and collaborators39 as HLA-DM sus-
ceptibility. Mellins and colleagues provided the first sys-
tematic evidence for the influence of both, MHCII
polymorphisms and the bound peptide on DM-
susceptibility,40 and further proved MHCII residues
influencing the interplay between DM-MHCII.41 Together
with Sollid's lab, they prove that a natural deletion in
DQA, Ser53, found in DQ2 results in a DM-insensitive
MHCII.42 The influence of the peptide bound to an MHCII
on DM susceptibility has been consistently connected with
the region of the P1 pocket, first related to pocket































FIGURE 2 Interplay between MHCII and ncMHCII. A, Schematic representation of the interplay of classical and ncMHCII highlighting
the two most relevant features that define the extent of editing as well as its requirement. CLIP affinity and intrinsic DM-susceptibility.
Classical MHCII molecules (in the middle) interact with invariant chain and DM directly, while the latter two do not interact with each other.
Note that only one chain is indicated for DR allotypes since all of them share the same DRA. In case of DQ allotypes: DQB1*06:02 has been
studied combined with DQA1*01:02 (DQ6), and DQA1*05:01 with DQB1*02:01 (DQ2). Also, to date DO is only assumed to interact with DM.
B, Expected impact of ncMHCII function on the immunopeptidome upon immunological challenge (eg, infection) for different MHCII
allotypes with known CLIP affinity and DM susceptibility in three different conditions, the absence of ncMHCII, the presence of only DM, and
the presence of DM-DO. The pool of pMHCII represents a theoretical distribution of abundances based on qualitative arguments of three types
of peptides indicated in the legend below the figure. The ability of MHCII molecules to bind pathogen derived peptides in the absence of DM is
set to null for clarity although depending on the infection, pathogen-derived peptides could be selected for presentation. CLIP, class II invariant
chain associated peptide; HLAII, human leukocyte antigens of class II; MHCII, major histocompatibility complex of class II molecules; nc,
nonclassical; pAPCs, professional antigen presenting cells; pMHCII, peptide-MHCII
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hydrogen bonds.44 While partial dissociation of the peptide
from this region was shown to be critical for DM interac-
tion45 anchoring of the peptide to this region and substitut-
ing residues located in the P9 pocket46 challenged this
view. Structural and biochemical analysis coupled to
extensive molecular dynamics simulations have allowed
us to define that indeed the dynamics of the pMHCII com-
plex are responsible for the DM susceptibility.47
Noteworthy, most of these conclusions have been
drawn from studies using DR and only a few allotypes of
DQ strongly associated to autoimmunity (eg, DQ2 and
DQ8 related to celiac disease and type 1 diabetes, or DQ6
related to multiple sclerosis and narcolepsy). A similar
behavior for DP proteins was expected based on the
sequence and structural similarities. However, the dis-
tinct DM and Ii requirements of some alleles of DP in cel-
lular settings to form stable complexes and egress from
the ER48 pinpointed potential dissimilarities. Recently, it
has been proposed that a particular polymorphism of DP,
DPBG84 results in a low CLIP affinity, which subse-
quently relies on peptide loading and editing by chaper-
ones of the MHCI pathway.30 While extremely
undogmatic, the contextualization of these findings into
general adaptive immune responses will be required to
define their physiological relevance.
5 | PEPTIDE EDITING BY HLA-DM
Mellins et al originally showed that genetic elements in
the central region of the HLAII were essential for the pre-
sentation of exogenous antigens49 and further mapped
the defective phenotype to DMA and DMB genes.50,51 The
same result was additionally confirmed by the Cresswell
using a different experimental model.52 Cresswell's,
Jensen's and Mellins' labs proved basically at the same
time the ability of DM to dissociate CLIP from MHCII
molecules. This function was extended to any peptide
with a suboptimal pocket occupation or low affinity. The
observation that DM worked at substochiometric concen-
trations in biochemical experiments53 and in cells,54
together with the Michaelis-Menten kinetics of the pep-
tide exchange reaction in the presence of DM55 led
researchers to consider this protein an enzyme. However,
the ability to recover MHCII molecules from aggregated
states or keep them in a peptide-receptive state in the
absence of peptide classified it as a chaperone.56 DM sam-
ples rare conformational states of peptide-MHCII
complexes,47 and also interacts transiently with MHCII
with partially dissociated peptides.45
Human HLA-DM57 and its murine homolog
H2-DM58 have been crystalized. Both proteins are struc-
turally very similar to classical MHCII proteins although
they bear substantial differences in the apical domains
conforming the binding groove of classical MHCIIs,
likely impeding the binding of any peptide to DM. Over
more than two decades researchers sought to define the
molecular mechanisms resulting in DM-mediated peptide
exchange. However, despite extensive mutagenesis analy-
sis mapping the lateral interaction of DM and DR in the
early 2000s,59 it took more than 10 years and a consider-
able protein engineering effort to solve the 3-D structure
of the DM-DR complex.34 The 3-D structure solved by
Wucherpfennig's group in two different states has facili-
tated the proposal of a reaction mechanism for the DM-
catalyzed peptide exchange of MHCII in which several
highly conserved residues in DM and MHCII are
involved. As mentioned in the previous section and
reviewed in33 DM seems to recognize the partial dissocia-
tion of the peptide from the P1 pocket and sense rare con-
formations in tightly bound peptide-MHCII complexes.
DM functions optimally at low-endosomal pH53
which was proposed to result from a pH sensing mecha-
nism confirmed partly by CD spectroscopy upon shift of
the pH of DM in solution.60 The three acidic residues in
the so-called acidic patch of DM (DMBE8, DMBD31, and
DMBE46 in humans) were suggested in the first 3-D
structure to be responsible for this pH-sensing.58 Indeed,
the 3D structure of DM in complex with DR1 confirmed
that DMB-E46 and D31 undergo a considerable
rearrangement upon interaction with DR1 which is fur-
ther modulated by the protonation state of the carboxyl
groups. Thus, at high pH deprotonation of D31 results in
a loss of a hydrogen bond that rearranges the DM struc-
ture and interacts in a less favorable manner with DR1.
Recently, we have shown that a naturally encoded DMB
variant (DMBD31V present in DMB*01:07) confers a con-
siderably less pH-sensitive activity.9
HLA-DM traffics independently of its interaction with
any other MHCII or the invariant chain through the cell.
The presence of a cytoplasmic sorting signal on DMB
facilitates its cellular sorting into vesicles and its
recycling through endosomal compartments.61 The sub-
cellular localization of DM and its catalytic pH-
dependency suggests that DM is preferentially located at
and more active in late endosomal compartments, which
in pAPCs are termed class II MHCII compartments
(CIIM) or multivesicular bodies (MVB).62 DM neverthe-
less is also found in all endocytic compartments where it
is supposed to contribute to a greater or lower extent to
peptide editing, and for some cell types even at the cell
surface.63 Although DM activity at the surface is usually
ignored, it has been shown that overexpression of a
mutant which is retained at the cell surface can indeed
favor extracellular peptide biding.64 Similarly, our recent
description of a DM allotype with a considerably higher
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activity at neutral pH may have a significant impact on
peptide editing at the cell surface.9
Unanue's lab revealed the importance of the distribu-
tion and pH-dependency of DM, showing that distinct
editing in different cellular compartments lead to the for-
mation of pMHCII isomers with the ability to trigger dif-
ferent types of T cells.24,25 Thus, type A CD4+ Th cells
recognize isomers formed in the presence of active DM
while type B CD4+ Th cells only recognize isomers
formed in the absence of DM. The preferential display of
each isomer in physiologically relevant contexts, namely
the thymus (type A) and the pancreas (type A and B) was
then correlated to the onset of CD4+ Th cell responses in
autoimmune diabetes.26 Many other types of experiments
have illustrated how DM function and even its expression
levels result in the increased or decreased presentation of
specific CD4+ Th cell epitopes although the only true rule
that one could consider is, that DM will select the
pMHCII complexes of highest kinetic stability from the
pool of available peptides (Figure 2B middle).
The field of mass spectrometry (MS) has facilitated
the study of the influence of DM function for the display
of antigenic peptides at a more global level.65-67 These
studies shed light on the preferential cellular compart-
ments for peptide loading of MHCII in the presence of
DM. Recent technical improvements have facilitated
deeper deconvolution of DM's influence in peptide selec-
tion for the immunopeptidome. In this regard, we have
recently reported the influence of different expression
levels of DM for the immunopeptidome of cell lines
expressing the high-CLIP affinity and high DM suscepti-
ble allotype DR3 (DRB1*03:01) developing a processing
algorithm and pipeline for improved analysis of this type
of data.68 The Jensen lab has also applied cell lines to
directly dissect the influence of DM in the
immunopeptidome of DQ in the most systematic
immunopeptidome analysis performed up to date of DM
function for these molecules.69 In general, the outcome
of these investigations is that DM reduces the abundance
of CD74/CLIP-related peptides and it facilitates the load-
ing of peptides with higher predicted affinity and optimal
pocket occupation from the endocytic pathway. Finally, a
recent study making use of MS, has shown that consider-
ing DM function and implementing it into epitope pre-
diction tools enhances cancer epitope prediction.70
6 | HLA-DO AS MODULATOR OF
DM ACTIVITY
Studying DO function has been considerably challenging.
DOA and DOB genes are spaced by many other HLA
genes, which led to a very late discovery of its functional
heterodimer. Besides, DO expression is restricted to B
cells and thymic epithelial cells, suggesting a subtler
function than that of DM. Furthermore, DO protein is
considerably unstable, defaulting any attempt to define
its biochemical activity. Indeed, DO only egress the ER71
when it is bound to DM, and recombinant expression for
in vitro experimentation is only facilitated upon introduc-
ing a P11A mutation that likely stabilizes the protein.
Interestingly, this particular mutation also facilitates the
egress of DO from the ER in cells independently of DM.72
Denzin and collaborators were able to show that DO
blocks DM activity in removing CLIP from MHCII mole-
cules. They used DO/DM purified from cellular extracts
and expressed this molecule in the T2 cell line.73 One
year later Kropshofer and collaborators showed that the
presence of DO favored the selection of specific peptides
by DR molecules rather than simply inhibiting CLIP dis-
sociation.74 More recently, Larry Stern's group has shown
by crystallography and kinetic measurements of peptide
exchange that DO acts as a substrate mimic that binds
tightly to DM blocking its catalytic activity on MHCII.75
This study also showed that DO´s groove lacks critical
hydrogen-bond donors, making peptide binding to DO
unlikely.75 In this context, Sadegh-Nasseri's group has
reported an intriguing observation consisting on the
direct interaction between DO and DR molecules in a
peptide-receptive conformation, which would promote
the direct selection of peptides.76 Several studies have co-
precipitated DM-DO-DR complexes74,77,78 proposing a
direct interaction of DM-DO complexes with MHCII as
well. Whether or not these findings are specific to the
experimental set up described, or they are representative
of a more universal peptide exchange mechanism
remains to be proven in systematic manner.
In nonoverexpressing systems (eg, B-LCLs or primary
cells), DO does not completely block DM activity. Thus,
under steady-state conditions, all DO present is bound to
DM while there is still around 50% of free DM from the
total pool of this molecule.3 DM-DO complexes egress
the ER and recycle between the plasma membrane and
the MIIC because of the cytoplasmic tail signal in
DMB.79 Interestingly, while DM-DO complexes seem to
localize to the peripheral membrane of MIIC, free DM
localizes to the MVB of these structures.79 Perhaps, such
distribution is owed to the DOB cytoplasmic tail, which
is known to be responsible for tuning the intracellular
distribution of DO.80 Denzin and Cresswell suggested
that MHCII present in each of these MIIC substructures
would therefore be loaded with a differential set of pep-
tides and account for a particular contribution to the net-
immunopeptidome.81 A recent study using CRISPR/Cas9
to Knock-out DO in the LG1 B-LCL has concluded that
DO presence leads to a broadened immunopeptidome
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containing a smaller fraction of kinetically stable high
affinity pMHCII complexes (Figure 2B right).82
DO influences the presence of epitopes of sources
internalized via receptor mediated endocytosis, and in
particular by the B cell receptor.83 Rather than a direct
interaction or DO-mediated peptide loading, the pH
dependency of the DM-DO interaction would result in
the dissociation of the complex at low pH. This mecha-
nism will result in DO degradation and an endosomal-
focused DM activity.83 However, DM-DO interaction,
once established, has proven to be pH-independent
in vitro84. Although these findings might not apply to a
cellular environment in the presence of the transmem-
brane domains, the mechanism for DM-DO dissociation
that precedes DM sorting into different structures in
MVB remains unsolved. To date, only a conformational
change on DOB dependent on the interaction with DMA
that facilitates DO egress from the ER has been defined
at the cellular level using monoclonal antibodies.85 An
alternative, yet hypothetical mechanism states that an
intracellular signaling event, likely triggered by TLR sig-
naling would be responsible for the dissociation of DM-
DO complexes.81
Another interesting aspect of DO refers to its particu-
lar expression pattern. DO is only expressed once B cell
development is complete, and its cellular levels are con-
siderably reduced during B-cell entry in germinal cen-
ters.3 Noteworthy, this decrease in DO levels does not
seem to be correlated to differences in DOB transcription
levels,86 and seems to be essential for B cells to gain
access to T cell help in this process.87 Besides B cells and
thymic epithelial cells, DO expression has been also
reported in some subsets of DCs21. As in B cells, in these
cells maturation also yields an increase in DO
expression.21
In summary, it seems that DO has evolved to promote
tolerance to self by inhibiting the presentation of self-
peptides other than CLIP in mature cells. This inhibition
would have important consequences on shaping the self-
peptidome during positive and negative selection of thy-
mocytes, during B cell maturation in the germinal cen-
ters, and on T cell activation by DCs.
7 | SMALL MOLECULES IN
“PEPTIDE EDITING”
Almost two decades ago Falk and collaborators demon-
strated that small molecules acting as hydrogen bond
donors could influence peptide exchange from MHCII.88
Afterwards the concept was exploited to generate the so-
called molecular loading enhancers (MLEs) and to show
that in some circumstances their function depended on
specific features of the MHCII allotypes.89,90 More impor-
tantly, such small molecules have been used in in vivo
experimentation demonstrating a great capacity to work
under physiological conditions.91 In recent years we have
seen how such small molecules could contribute not only
to favor peptide exchange but also to interfere directly
with peptide binding for MHCI with important conse-
quences for immune reactions as reviewed in92. Thus,
crossing the line from a transiently interacting MLE to a
stable MHCII groove-binding molecule potentially caus-
ing adverse drug reactions is of critical importance in
attempts to manipulate the MHCII immunopeptidome
by small molecules.
Noteworthy, the Wucherpfennig group reported that
there are small molecules capable of tuning DM func-
tion.57 Certain fluorinated compounds are able to
increase the ability of DM to catalyze peptide exchange.
Interestingly, the authors proposed that these small mole-
cules interact with DM within a region that has been
mapped a posteriori to the interface between DM-DR.
Two key aspects remain unclear: the molecular mecha-
nism of these molecules to interfere with DM function,
and whether they also influence DM-DO interaction.
While their application in vivo, is challenging, using
these molecules for in vitro experimentation could lead
to additional molecular insights and a better understand-
ing of DM and DO function.
8 | BIOLOGICAL IMPLICATIONS
OF PEPTIDE EDITING
The function of DM and DO has been evaluated and cor-
related to clinical conditions mostly upon investigation in
settings restricted to specific peptides. The influence of
DM has been studied in the context of the editing of epi-
topes related to autoimmunity, allergy or infection (eg,
GAD65, CII, Insulin, BetV1, MTB) and for DO, on the
display of self-antigens related to allogenic stem cell
transplantation (reviewed in Reference 93). While
extremely appealing, the sometimes-contradictory effects
of DM and/or DM/DO complicate the assessment of a
preferential function on editing epitopes related to a par-
ticular disease. It is very unlikely that a clinical condition
is only driven by the presentation of one single peptide
by an MHCII.
Several murine models have been used to understand
the physiological relevance of DM and DO (see Table 1).
These models have shown that DM and DO are essential
for proper thymic selection, for adequate immune
responses to pathogens, and for the development of auto-
immune phenotypes. Thus, DM and DO function
together for the optimization of antigen selection
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favoring effective responses to pathogens while preserv-
ing self-reactivity at low levels. Of note, the MHCII locus
in the mouse shows relevant differences with regard to
humans. Mice only have H2-A, or H2-A and H2-E genes
(orthologues of DQ and DR, respectively), and there are
two H2-DMb genes which seems to be differentially
expressed in response to cytokines but yield functionally
active H2-DM heterodimers (reviewed in Reference 93).
The global impact of peptide editing for T cell devel-
opment, and in particular of DM function, is more pro-
nounced on MHCII backgrounds with high affinity for
CLIP. In this context, positive and negative selection are
mainly driven by MHCII-CLIP stability and CD4+ Th
numbers in peripheral tissues are considerably reduced
(up to 50%) as a result of defective positive selection in
H2-M-deficient mice. Furthermore, the pool of CD4+ Th
cells available in peripheral tissues reacts strongly to the
peptidome displayed by pAPCs of syngeneic wild-type
mice in mixed lymphocyte reactions.94-96 This is indica-
tive of altered negative selection in the absence of
H2-DM. In case of haplotypes (single MHCII or mixed)
with low MHCII-CLIP affinity, thymic selection seems to
be less affected for conventional CD4+ Th cells and conse-
quently the extent of reactivity to syngenic, or MHCII-
matched strains is more variable.97-99 In these low
MHCII-CLIP affinity backgrounds, however, it has been
shown that the frequency of Treg in peripheral tissues is
higher in the absence of DM.100,101 The implications of
the lack of DO for thymic selection has been studied only
in the murine H2-b background (high MHCII-CLIP affin-
ity)102,103 and only Perraudeau and collaborators reported
a slight increase in the total number of CD4+ Th cells in
lymph nodes of KO animals (9.4% total cells) compared
to wild-type (7.6%) animals.103 Following a completely
different strategy to understand protein function, the
Denzin lab ectopically expressed human DO in murine
DCs on the diabetogenic (low affinity MHCII-CLIP)
background H2-Ag7 of the NOD mouse and reported nei-
ther influence on T cell numbers nor selective
reactivities.104
The impact of DM and DO on CD4+ Th-mediated
immune mechanisms has been evaluated in different
contexts. Following the original reports on strong reactiv-
ities of T cells from wt mice to cells of syngenic mice
missing DM,94-96,105 van Kaer and collaborators
pinpointed the importance of the peptide-repertoire asso-
ciated to MHCII for allo-reactivity.106 Subsequently it
was shown that DM loss has a dramatic effect on murine
cardiac transplantation.107 In case of DO, there is no
direct report assessing the influence of lack of function
for allo-responses or transplantation conditions. Their
influence in infection is better documented. DM focuses
and restricts the immune response towards a very limited
number of high-stability peptides, which are called
“immunodominant”.108 The Bikoff lab109 determined
that for H2-DM−/− mice, not only is the immuno-
dominance of antigenic peptides broader when DM is
absent, but the entire immune response shifts from I-Ad
presentation in the wild-type to I-Ed presentation in the
KO mouse. Furthermore DM seems to be responsible for
murine control of Mycobacterium tuberculosis infection
under laboratory conditions.110 A unifying conclusion
TABLE 1 Murine models for studying DM and DO function






































I-A low Very low Protected from diabetes




Not defined Not defined Protected from retroviral infection
Neutralizing antibodies
10
Note: Described murine models in which DM and DO function has been studied. Haplotype, affinity for CLIP (relative), DM susceptibility of
each MHCII, and the main observed consequences are indicated. References for each of the models are also given.
Abbreviations: CLIP, class II invariant chain associated peptide; MHCII, major histocompatibility complex of class II molecules.
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from all of these studies is that in the haplotypes bearing
MHCII allotypes with a low affinity for CLIP, the
antigen-presenting function seems to be less affected.
Tourne et al.111 also described that DM−/− mice were able
to respond to certain viral infections, although antibody
responses were generally less efficient than in the wild
type mouse. The Eisenlohr laboratory has demonstrated
that only some viral epitopes require the presence of DM
for presentation, and that efficient immune responses
rely mostly on the antigen processing of endogenously
synthesized virions.23 In the case of bacterial infection,
however, DM seems to be required for an appropriate
immune response.110 The requirement of DM function
for mounting efficient antibody responses to pathogens
was later evaluated, and the absence of DM was associ-
ated with an impaired ability to form germinal centers
for B-cell maturation.112
There are considerable physiological differences
between humans and mice regarding antigen presenta-
tion and/or T cell responses although the fundamental
mechanisms affected by altered editing in these models,
are likely to apply to humans as well. To date fundamen-
tal research questions, such as the impact of peptide
editing in T cell selection, have been solved using inbred
strains. However, recent findings by Denzin and
Golovkina have demonstrated an impact of genetic varia-
tions of ncMHCII for adaptive immune responses. A
H2-Ob null allele, found in the I/LnJ strain protects ani-
mals from retroviral infections by facilitating the produc-
tion of neutralizing antibodies.10 To what extent these
findings correlate and/or apply to humans is difficult to
predict although they demonstrated the different func-
tion of human DO depending on allelic variants of DOB.
In particular, rs144814623 found in a gain of function
DOB variant (high DM inhibition) is in LD with
rs4273729 “A” found in DQA2 alleles that have been
associated with viral persistence while s4273729 “G” is
related to viral clearance. We have been able to demon-
strate that human DM allelic variants impose distinct
functional profiles that also affect epitope display and T
cell activation9 albeit these variants have not been yet put
into any clinical context.
9 | GENETIC ASSOCIATION
STUDIES IN HUMANS TO
UNDERSTAND ncMHCII FUNCTION
Classical HLA class II allelic variants have been linked to
autoimmune disorders, allergies and other clinical condi-
tions in which CD4+ Th cells play important roles. The
main mechanism accounting for the contribution of these
allelic variants to health and disease lies on their ability
to bind and present antigenic peptides recognized by
reactive CD4+ Th cells. In this context, the discovery of
ncMHCII, and their function, motivated genetic associa-
tion studies evaluating a direct link between ncMHCII
genes, DMA and/or DMB mostly, and several
autoimmune-related disorders. Despite statistically sound
outcomes (reviewed by us in Reference 93), there was no
clear correlation for any genetic variant of ncMHCII to
disease. The low frequency of allelic variants of ncMHCII
genes impede the assessment through conventional asso-
ciation studies with low number of samples.
Genome wide association studies of big datasets could
overcome these problems. Interestingly, in recent reports
it has been shown that certain natural variations in
ncMHCII genes with frequencies higher than 5% are
linked to particular disease outcomes as for instance
rheumatoid arthritis113 and systemic lupus
erythematosus.114 Other approaches have shown a corre-
lation between specific ncMHCII genes and autoimmune
diseases115 as well as between allelic variants and viral
infections.116 However, very low frequencies mask associ-
ations unless specific considerations are taken into
account.117 The comparison of the functional features of
any of the genetic variants related to disease with those
un-related could contribute to determine the biological or
physiological relevance of peptide editing. This includes
those polymorphisms affecting gene expression that have
already been detected in associations to diseases.113,114
Thus, besides the identification of causative variants for
diseases, the next biggest issue faced in the field is the
development of reliable and physiologically relevant
functional assays. On the one hand, we should consider
appropriate cellular models based on physiologically rele-
vant expression levels of MHCII and ncMHCII proteins
to solve basic mechanistic questions. On the other hand,
animal models should incorporate human transgenes or
being reconstituted with the complete human immune
system. Alternatively, we could also draw conclusions by
engineering murine backgrounds in which specific
ncMHCII functions are tuned.
10 | CONCLUDING REMARKS
DM and DO function has been characterized at the
molecular, cellular and organismic level using a handful
of representative MHCII allotpyes. This research has
been fundamental in determining that the impact of
peptide editing on T cell responses, and hence adaptive
immunity, significantly depends on the MHCII allotype.
While we are now starting to have a clearer picture on
their function, one of the biggest problems for scoring
the impact of peptide editing in a broad sense, is the
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distinct behavior of MHCII allotypes. Systematic analy-
sis of peptide editing on individual MHCII allotypes
should contribute to defining models for studying the
influence of peptide editing. Adding to complexity, most
(immunopeptidomic) studies so far have not taken into
account actual human haplotypes, neglecting nonaddi-
tive effects of peptide loading and exchange under com-
petitive conditions. Further key remaining questions in
DM and DM-DO peptide editing include: (a) how the DM-
DO ratio is regulated in cells under steady state and matu-
ration conditions; (b) if the DM-catalyzed peptide
exchange shown for DR applies to other MHCII allotypes.
Furthermore, recent findings from our lab and from
Denzin-Golovkina have pinpointed the impact of natural
variations of ncMHCII on peptide-MHCII editing. Indeed,
the study by Denzin-Golovkina have even shown the tre-
mendous impact these processes have in immune
responses to pathogens. Since it is very hard to extrapolate
findings in murine models to human biology, other experi-
mental models are required to evaluate the impact of natu-
ral variations in ncMHCII genes for human immunology.
It remains to be unraveled whether natural variations on
ncMHCII genes might differentially modulate peptide
editing of specific haplotypes. In this case, genetic studies
in conjunction with functional characterization of natural
variants in appropriate experimental models will be
essential.
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